Two Year Treatment w/Teriflunomide vs. Placebo for MS
ID Number 08-0364Principal Investigator(s)
Teresa M. DeAngelis
Department(s) or Division(s)
The purpose of this study is to evaluate the effectiveness and the potential risks of teriflunomide at the doses of 7 and 14 mg once daily compared to placebo (substance which contains no active medication) in the treatment of patients presenting with their first neurological episode suggestive of MS and who have abnormalities on a Brain MRI that shows a risk of developing MS.
Recruiting Patients: Yes